Skinvisible, Inc. (OTCBB: SKVI) StockGuru SKVI Profile
Skinvisible’s polymer delivery vehicles and related compositions hold active ingredients on the skin for extended periods of time when applied topically and is used in over the counter licensed products.
Let’s look at some of the products that SKVI has licensed which will be the ongoing source of revenue for the company through royalties and polymer sales.
DermSafe®, the Company’s hand sanitizing lotion, was proven effective with a greater than 99.99% inactivation/kill on the H1N1 influenza A virus.
- SKVI has licensed DermSafe to Rhei Pharmaceuticals for commercial sales in Europe and China
- SKVI has licensed DermSafe to Alto Pharmaceuticals for commercial sales in Canada
- SKVI has licensed DermSafe to Mayquest Pharmaceuticals for commercial sales in Singapore and S.E. Asia
Skinvisible licenses Invisicare® to established brand manufacturers of dermatological, medical, cosmetic, and skincare markets and marketers of prescription and over-the-counter products.
With the exception of sales to one vendor, Skinvisible’s policy is to only sell Invisicare® to vendors that have executed a license agreement with the Company. This means SKVI earns not only income from the licensing agreement but has a solid source of ongoing revenues from royalties.
Over-the-Counter License Products
Safe4Hours – SKVI has licensed two products sold under the name Safe4Hours in North America. Both products are being sold now with the first aid antispetic skin protectant in over 7,000 Walgreen stores in the US. SKVI receives revenue from polymer sales plus ongoing royalties.
Solerra – SKVI has licensed worldwide rights to its sunless tanning lotion for use in an easy to apply mitt. Solerra market the products in the US & Canada with a European expansion planned. SKVI receives revenue from polymer sales plus ongoing royalties.
Acne product formulations – SKVI has licensed three products to two Dermatology companies in Turkey and S. America. As these products are designated drugs both companies are seeking regulatory approvals and should be selling in 2012. SKVI will receive revenue from polymer sales plus royalty income.
To date SKVI has licensed nine products to six companies for sale in 14 countries plus one company licensing one product for the world.
All of the above companies have paid an upfront license fee to SKVI for exclusive rights to the products for the marketing rights for specific countries – some as high as $1 million. SKVI will now receive income based on polymer sales to each company plus ongoing royalties based on product sales. All license agreements are for the life of the patent or 20 years whichever is greater.
There it is – SKVI, a US pharmaceutical company with the opportunity to earn income in every country in the world in an industry that is recession proof – skincare & pharmaceuticals.
Skinvisible, Inc. / Skinvisible Pharmaceuticals, Inc.
6320 S. Sandhill Road, Suite 10
Las Vegas, Nevada, 89120 U.S.A.
Phone: 702.433.7154
Fax: 702.433.7192
Email: [email protected]
Phone: 801.485.7978
Fax: 801.466.6877
About Invisicare: Invisicare is Skinvisible’s patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. It is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time resisting both wash off and perspiration. Invisicare can control the release of actives, reduce irritation and can eliminate some costly manufacturing processes. It is non-occlusive and allows for normal skin respiration while protecting against environmental irritants. www.invisicare.com
About Skinvisible Pharmaceuticals, Inc.
Skinvisible is a research-and-development company that licenses its proprietary formulations made with Invisicare, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing irritation. Skinvisible receives a combination of research and development fees, license fees, and royalties for the life of the patent. Skinvisible’s value also lies in its ability to continually generate new IP on topical products formulated with Invisicare.
Pentony Enterprises LLC is STOCKGURU.COM. 1601 Berwick Drive, McKinney, Texas 75070 – (469) 252-3030. Disclosure: StockGuru entered into an investor relations consulting and market awareness contract on July 12, 2010. The company has agreed to pay us five thousand dollars per month in cash for the period of six months, totaling thirty thousand USD. StockGuru was previously compensated 500,000 144 restricted common shares by the company for profile coverage for the period ending January 30, 2010. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. To further clarify, we will not be buying or selling shares for the period of July 12, 2010 through January 12, 2011. We hold no shares and will not be receiving further compensation that is share related during this period. Pentony Enterprises is not a registered investment adviser or a broker/dealer. StockGuru makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.